HeartBeam (NASDAQ:BEAT – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect HeartBeam to post earnings of ($0.09) per share and revenue of $0.08 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.
HeartBeam (NASDAQ:BEAT – Get Free Report) last released its earnings results on Thursday, August 13th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). On average, analysts expect HeartBeam to post ($0.37) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.
HeartBeam Stock Up 0.9%
Shares of BEAT opened at $0.41 on Tuesday. The firm’s fifty day simple moving average is $0.43 and its two-hundred day simple moving average is $0.83. HeartBeam has a 12 month low of $0.35 and a 12 month high of $4.00.
Analyst Ratings Changes
Several research analysts have recently weighed in on BEAT shares. Weiss Ratings raised HeartBeam from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 30th. HC Wainwright restated a “neutral” rating on shares of HeartBeam in a research report on Tuesday, October 6th. Maxim Group started coverage on HeartBeam in a research note on Tuesday, July 14th. They set a “buy” rating and a $2.00 target price for the company. Finally, Wall Street Zen upgraded HeartBeam to a “sell” rating in a report on Saturday, October 10th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, HeartBeam has a consensus rating of “Moderate Buy” and a consensus price target of $4.00.
Get Our Latest Stock Report on BEAT
HeartBeam Company Profile
HeartBeam, Inc is a medical technology company developing portable and digital solutions for cardiac monitoring. Its proprietary technology is designed to capture, analyze and transmit electrocardiogram (ECG) data outside traditional clinical settings, with a focus on helping identify cardiac events such as atrial fibrillation and heart attacks.
The company’s flagship product is the HeartBeam AIMIGo system, which combines a compact, credit-card-sized ECG device with a smartphone application.
Featured Stories
- Five stocks we like better than HeartBeam
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
